[go: up one dir, main page]

WO2015151079A3 - Auristatin analogues and their conjugates with cell-binding molecules - Google Patents

Auristatin analogues and their conjugates with cell-binding molecules Download PDF

Info

Publication number
WO2015151079A3
WO2015151079A3 PCT/IB2015/054653 IB2015054653W WO2015151079A3 WO 2015151079 A3 WO2015151079 A3 WO 2015151079A3 IB 2015054653 W IB2015054653 W IB 2015054653W WO 2015151079 A3 WO2015151079 A3 WO 2015151079A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
cell
binding molecules
analogues
auristatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/054653
Other languages
French (fr)
Other versions
WO2015151079A2 (en
Inventor
Qingliang YANG
Robert Y. Zhao
Hangbo YE
Shun GAI
Junxiang JIA
Yuanyuan Huang
Xing Li
Huihui GUO
Hongsheng Xie
Wenjun Li
Xiaomai ZHOU
Chengyu Yang
Xiaotao ZHUO
Linyao ZHAO
Minjun CAO
Chen Lin
Jie Peng
Zhicang YE
Jun Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Dac Biotech Co Ltd
Original Assignee
Hangzhou Dac Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Dac Biotech Co Ltd filed Critical Hangzhou Dac Biotech Co Ltd
Priority to CN202310609261.2A priority Critical patent/CN116726190A/en
Priority to CN201580080907.6A priority patent/CN107921144B/en
Priority to PCT/IB2015/054653 priority patent/WO2015151079A2/en
Publication of WO2015151079A2 publication Critical patent/WO2015151079A2/en
Publication of WO2015151079A3 publication Critical patent/WO2015151079A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided are analogues of auristatins, in particular monomethyl auristatin F (MMAF), as cytotoxic agents, conjugates of such agents with a cell-binding agent, the preparation and the therapeutic uses of these cytotoxic agents and conjugates thereof to arrest or retard abnormal cell growth and /or proliferation.
PCT/IB2015/054653 2015-06-20 2015-06-20 Auristatin analogues and their conjugates with cell-binding molecules Ceased WO2015151079A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202310609261.2A CN116726190A (en) 2015-06-20 2015-06-20 Aureostatin analogs and conjugate conjugates thereof with cell-binding molecules
CN201580080907.6A CN107921144B (en) 2015-06-20 2015-06-20 Auristatin analogs and their conjugates with cell-binding molecules
PCT/IB2015/054653 WO2015151079A2 (en) 2015-06-20 2015-06-20 Auristatin analogues and their conjugates with cell-binding molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/054653 WO2015151079A2 (en) 2015-06-20 2015-06-20 Auristatin analogues and their conjugates with cell-binding molecules

Publications (2)

Publication Number Publication Date
WO2015151079A2 WO2015151079A2 (en) 2015-10-08
WO2015151079A3 true WO2015151079A3 (en) 2016-05-06

Family

ID=54241396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/054653 Ceased WO2015151079A2 (en) 2015-06-20 2015-06-20 Auristatin analogues and their conjugates with cell-binding molecules

Country Status (2)

Country Link
CN (2) CN116726190A (en)
WO (1) WO2015151079A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12324840B2 (en) 2017-02-20 2025-06-10 Zhejiang Teruisi Pharmaceutical Inc. CD20-targeted antibody coupling pharmaceutical preparation

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
TW201740979A (en) * 2016-02-29 2017-12-01 瑪德瑞高製藥公司 HSP90 inhibitor drug conjugates
KR102456433B1 (en) 2016-03-02 2022-10-19 에자이 알앤드디 매니지먼트 가부시키가이샤 Eribulin-based antibody-drug conjugates and methods of use
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN116672463A (en) * 2017-02-17 2023-09-01 浙江特瑞思药业股份有限公司 Preparation method of targeted CD20 antibody coupling drug, antibody coupling drug and application thereof
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JP7202301B2 (en) * 2017-08-10 2023-01-11 住友ファーマ株式会社 Hemiasterin derivatives and their antibody-drug conjugates
EP3666787B9 (en) * 2017-08-10 2024-08-28 Sumitomo Pharma Co., Ltd. Antibody-drug conjugates including hemiasterlin derivative
SG11202004192XA (en) * 2017-11-29 2020-06-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd2+ cells
AU2018374634A1 (en) 2017-12-01 2020-05-28 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2019142147A2 (en) * 2018-01-18 2019-07-25 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd134+ cells
CN108912212B (en) * 2018-06-28 2019-08-30 中山大学附属口腔医院 A kind of polypeptide and its application with CD105 specific binding
AU2019310430A1 (en) * 2018-07-23 2021-02-25 Magenta Therapeutics, Inc. Use of an anti-CD2 antibody drug conjugate (ADC) in allogeneic cell therapy
CN109187941B (en) * 2018-08-31 2022-04-29 暨南大学 Application of CD4+ CD70+ T cell subset in preparation of kit for auxiliary diagnosis of very severe aplastic anemia
US12178879B2 (en) 2019-02-13 2024-12-31 Sumitomo Pharma Co., Ltd. Hemiasterlin derivative and antibody-drug conjugate thereof
CN113412271B (en) 2019-02-13 2024-10-22 住友制药株式会社 Having cysteine residues Hamiltelin derivatives of (C)
JP7560255B2 (en) * 2019-02-13 2024-10-02 住友ファーマ株式会社 Medicine containing antibody-drug conjugate containing hemiasterlin derivative
CN113121639B (en) * 2019-12-30 2024-05-14 江苏恒瑞医药股份有限公司 Aureostatin analogue and conjugate thereof, preparation method and application thereof
CN110940764B (en) * 2019-12-31 2022-06-28 湖南九典制药股份有限公司 A kind of separation method of statin optical isomers
CN115190882A (en) * 2020-03-09 2022-10-14 西格马-奥尔德里奇有限责任公司 Efficient preparation of dolastatin and auristatin analogs via common intermediates
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
CN111558044B (en) * 2020-06-01 2022-02-11 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Pharmaceutical composition containing sunitinib, and preparation and application thereof
CN111393346B (en) * 2020-06-02 2020-08-25 凯莱英生命科学技术(天津)有限公司 Synthesis method of N-Boc-Dolaprine and Boc-Dap DCHA
AU2021379015A1 (en) * 2020-11-16 2023-06-22 The Cleveland Clinic Foundation Anti-cd6 antibody conjugates for treating t-cell and b-cell mediated disorders, and t-cell and b-cell cancers
CN114073702B (en) * 2021-03-05 2023-12-12 中以海德人工智能药物研发股份有限公司 Use of quinolones for treating or preventing hepatitis B
CN118236514B (en) * 2022-12-24 2025-10-31 津药生物科技（天津）有限公司 Antibody-glucocorticoid conjugates and uses thereof
CN120917016A (en) 2023-05-06 2025-11-07 荣昌生物制药(烟台)股份有限公司 A method for preparing an intermediate of an olistatin derivative
CN120957759A (en) * 2023-05-12 2025-11-14 四川科伦博泰生物医药股份有限公司 Compound with anti-tumor effect and preparation method and application thereof
CN116482370B (en) * 2023-06-25 2023-08-25 北京大学人民医院 Antibody combination for screening plasma cell tumor treatment target and/or abnormal phenotype and application thereof
CN117430660B (en) * 2023-09-04 2024-10-18 诺灵生物医药科技(北京)有限公司 Auristatin F analogs and their antibody-drug conjugates and their applications

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005081711A2 (en) * 2003-11-06 2005-09-09 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2009052431A2 (en) * 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
WO2012143497A2 (en) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Novel binder-drug conjugates (adcs) and their use
WO2014009774A1 (en) * 2012-07-12 2014-01-16 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
WO2014080251A1 (en) * 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005081711A2 (en) * 2003-11-06 2005-09-09 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2009052431A2 (en) * 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
WO2012143497A2 (en) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Novel binder-drug conjugates (adcs) and their use
WO2014009774A1 (en) * 2012-07-12 2014-01-16 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
WO2014080251A1 (en) * 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12324840B2 (en) 2017-02-20 2025-06-10 Zhejiang Teruisi Pharmaceutical Inc. CD20-targeted antibody coupling pharmaceutical preparation

Also Published As

Publication number Publication date
CN107921144A (en) 2018-04-17
CN107921144B (en) 2023-11-28
WO2015151079A2 (en) 2015-10-08
CN116726190A (en) 2023-09-12

Similar Documents

Publication Publication Date Title
WO2015151079A3 (en) Auristatin analogues and their conjugates with cell-binding molecules
EP3981434A4 (en) Anti-b7-h4 antibody-drug conjugate and medicinal use thereof
CA2956871C (en) Compounds active towards bromodomains
WO2015165413A8 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX2020009857A (en) Il-2 conjugates.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
WO2012143497A3 (en) Novel binder-drug conjugates (adcs) and their use
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
SG11201811697SA (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
EP3566750A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
EP3412292B8 (en) Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
IL289932A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
EP4327887A3 (en) Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease
IL289096A (en) Parenteral lysophosphatidylcholine formulations such as lpc-dha, lpc-epa and their use in therapy
WO2014134457A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
WO2015159155A3 (en) Novel ademetionine formulations
EP4342461A3 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
IL291388B1 (en) Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
WO2018132696A3 (en) Stomach acid-stable and mucin-binding protein-polymer conjugates

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15772876

Country of ref document: EP

Kind code of ref document: A2